Skip to content

Development and Validation of a Simple Diagnostic Tool Predictive of the Aseptic Character of Joint Effusion

Development and Validation of a Simple Diagnostic Tool Predictive of the Aseptic Character of Joint Effusion

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03979937
Acronym
PRASEPT
Enrollment
328
Registered
2019-06-10
Start date
2020-02-15
Completion date
2022-03-01
Last updated
2022-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Joint Effusion, Septic Arthritis, Arthritis

Brief summary

Development and validation of a simple diagnostic tool predictive of the aseptic character of joint effusion in the primary care setting.

Detailed description

In accordance with guidelines and because of the potential gravity that this situation could represent, any joint effusion must be considered as a septic arthritis until proven otherwise, thus justifying an arthrocentesis and an adequate treatment. Nevertheless, because of epidemiology in primary care, this pragmatic attitude is quite commonly obscured and practices vary according to the experience of the doctor and his personal habits. As a result, the arthrocentesis is not commonly performed and anti-inflammatory treatment, whether based on NSAIDs or corticosteroids, is even sometimes administered to the patient despite the contrary guidelines. Although usually effective, this attitude is however not without risks. In this context, it seems interesting to develop a simple, reproducible and applicable diagnostic tool in a primary care setting for predicting the risk of septic arthritis. This study is therefore aimed at the development and validation of a predictive score based on simple clinical and paraclinical data (such as the macroscopic appearance of the synovial fluid removed) in a patient with an effusion, whatever either the clinical presentation, whether isolated or integrated in a more complex clinical presentation, whether associated with locoregional inflammatory or general signs or not.

Interventions

Arthrocentesis to determine the nature of the effusion (septic or aseptic).

Sponsors

Centre Hospitalier le Mans
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult patient (age ≥ 18 years) * Hospitalized in the conventional hospitalization unit or day hospitalization unit or received in consultation within the Rheumatology or Infectious Diseases units at the Le Mans General Hospital * presenting at least one joint effusion at clinical examination * Interesting a native, nonoperated joint, accessible to a puncture based on clinical markers, determined by palpatory anatomy * Affiliated to social security * No opposition expressed after written information

Exclusion criteria

* General antibiotic therapy in progress or completed less than 15 days before * Failure to perform the arthrocentesis * Person subject to a legal protection measure, not allowing his compliance with the study * Participant already included in another study (exclusivity clause)

Design outcomes

Primary

MeasureTime frameDescription
Presence of a septic arthritis10 days after the arthrocentesis.Presence of more than 2000 cells/mL and bacterial growth in the articular fluid.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026